Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2022-10-20 Earnings Release
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Earnings Release 2022
Earnings Release Classification · 1% confidence The document is explicitly titled "DELÅRSRAPPORT juli – september 2022" (Interim Report July – September 2022) and contains a detailed financial summary for the third quarter (Q3) and the first nine months (January – September) of 2022, including key metrics like Net Sales, Operating Income, and Earnings Per Share, comparing them to the previous year. This structure and content clearly identify it as a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). It is not an Earnings Release (ER) because it is comprehensive, not just highlights, and it is not a 10-K because it covers only nine months. 9M 2022
2022-10-20 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'INTERIM REPORT' and covers the period 'July – September 2022'. It contains comprehensive financial summaries, including income statements, cash flow data, and key financial performance indicators for both the third quarter and the year-to-date period. It also includes management commentary from the CEO and detailed operational updates, which is characteristic of an interim financial report rather than a simple earnings release or a publication announcement. Q3 2022
2022-10-20 English
BioArctic presenterar valberedningen
Governance Information Classification · 1% confidence The document is a press release from BioArctic AB dated October 18, 2022, announcing the composition of the Nomination Committee (Valberedningen) ahead of the 2023 Annual General Meeting (AGM). The text explicitly details the instruction for appointing the committee members based on shareholder structure as of September 30, 2022, and lists the appointed members. This content directly relates to the preparatory work and governance structure surrounding the AGM, specifically concerning the nomination of directors and setting remuneration. This falls under Governance Information (CGR) or potentially AGM Information (AGM-R). Since the core subject is the composition and mandate of the body responsible for nominating directors and setting AGM proposals, it aligns most closely with Governance Information (CGR), which covers internal rules and board structure, or AGM-R if it were a presentation. Given the focus on the *Valberedning* (Nomination Committee) structure and mandate, CGR is a strong fit, but the context is explicitly tied to the upcoming AGM process. However, the definitions provided suggest AGM-R is for presentations/materials *shared during* the AGM. Since this is an announcement *before* the AGM about the committee that prepares proposals *for* the AGM, and it deals with board composition/governance structure, CGR is appropriate. Alternatively, since it is a specific announcement about a body related to the AGM, and it is not a DEF 14A (Remuneration) or DVA (Voting Results), I will classify it as Governance Information (CGR) as it details the structure of a key governance body. Given the strong focus on the AGM preparation, AGM-R is also plausible, but CGR covers the structure of such committees better. Let's re-evaluate: The document announces the members of the committee responsible for proposing board members and remuneration for the *next* AGM. This is a core governance function announcement. I will select CGR.
2022-10-18 Swedish
BioArctic presents Nomination Committee
AGM Information Classification · 1% confidence The document is a press release announcing the composition of the Nomination Committee established following the previous Annual General Meeting (AGM) and outlining the process for submitting proposals for the upcoming 2023 AGM. It specifically mentions the 'Annual General Meeting' and the 'Nomination Committee' structure and process. This content directly relates to the governance and preparatory steps for the AGM. While it is an announcement, the subject matter is highly specific to AGM procedures, making 'AGM Information (AGM-R)' the most appropriate classification over a general 'Report Publication Announcement (RPA)' or 'Governance Information (CGR)', as it details the committee responsible for AGM proposals.
2022-10-18 English
Lecanemab uppnådde både det primära och alla sekundära effektmått i fas 3-studien Clarity AD i tidig Alzheimers sjukdom med hög statistisk signifikans
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces positive Phase 3 clinical trial results (Clarity AD study) for the drug lecanemab in treating early Alzheimer's disease. It details efficacy endpoints, safety data (ARIA), and future regulatory plans (FDA, PMDA submissions). This format—a formal announcement of significant operational/clinical milestones, often released to the public market via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of clinical trial results, which often accompanies or precedes formal financial reporting, and it is not the full financial report (10-K) or a comprehensive interim report (IR), it fits best as an Earnings Release (ER) which typically covers key operational and clinical achievements for the period, or RNS as a general regulatory announcement. Given the focus on clinical trial success and regulatory milestones, ER is a strong candidate, but RNS is the most appropriate fallback for non-standard, material announcements. However, many companies issue press releases detailing major clinical trial readouts as their primary means of communicating material non-financial news to the market, which often aligns with the function of an ER or a specific announcement type. Since there is no specific category for 'Clinical Trial Results Announcement', and it is a material announcement, RNS is the safest general regulatory classification. Upon review, ER (Earnings Release) often includes major operational news like this, but RNS (Regulatory Filings) is the catch-all for material announcements not covered elsewhere. Given the content is a major clinical update, and not strictly financial results, RNS is the most accurate fit among the provided options for a general regulatory disclosure.
2022-09-28 Swedish
Lecanemab phase 3 Clarity AD study in early Alzheimer’s disease meets primary and all key secondary endpoints with high statistical significance
Earnings Release Classification · 1% confidence The document is explicitly titled "Press release" and announces positive topline results for the Lecanemab phase 3 Clarity AD study. It details clinical endpoints, statistical significance, adverse events (ARIA), and future regulatory filing timelines (FDA PDUFA date, EU/Japan submissions). This content structure—a formal announcement of key financial/clinical results for a reporting period (the study completion)—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on the immediate release of study results rather than a comprehensive periodic financial report (10-K or IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), which covers initial announcements of periodical results/major developments. Given the context of a major clinical trial result announcement, ER is appropriate, although RNS could also apply if it were purely regulatory. However, the detailed nature of the results points towards ER. FY 2022
2022-09-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.